DoW Rare Cancers Idea Development Award | HT942526RCRPIDA

FY26 DoD Rare Cancers Research Program (RCRP) Idea Development Award (IDA) FAQs

1) What is this funding opportunity?

The FY26 Department of Defense Rare Cancers Research Program (RCRP) Idea Development Award (IDA) is a discretionary grant opportunity administered through the Defense Health Agency Contracting Activity (DHACA). It supports rare cancer research projects that are ready to move beyond the earliest stage of conception and into the next step of development.

2) What is the official funding opportunity identifier?

The Funding Opportunity Number is HT942526RCRPIDA, and the CFDA listing referenced is 12.420.

3) What is the main purpose of the Idea Development Award?

The award is designed to advance promising rare cancer research concepts that are already sufficiently formed and supported. The intent is to generate high-impact findings and open new lines of investigation that can meaningfully advance understanding, prevention, diagnosis, or treatment of rare cancers and ultimately benefit patients.

4) What kinds of projects are a good fit for this award?

Projects that sit in a practical middle ground: not so early that they are purely speculative or unsupported, but still developmental and positioned to benefit from structured funding to move the idea forward. The program emphasizes innovation that is mature enough to build on, paired with a credible path to producing influential results in rare cancers.

5) Does the program allow exploratory research?

Yes. The program explicitly allows and encourages including an exploratory aim or sub-aim within the project. This exploratory component is intended for discovery-driven work that helps de-risk the idea, refine a hypothesis, identify a target or biomarker, or generate enabling information that strengthens the overall research direction.

6) Is this award meant for early brainstorming or very preliminary concepts?

No. A defining feature is that it is not focused on purely speculative brainstorming. Applicants are expected to propose work that is already sufficiently formed and supported to justify a next step of development.

7) What does the program mean by "innovation that is mature enough to build on"?

It means the idea should be innovative, but also supported by a rationale and evidence base that makes the next developmental step credible. The project should be designed to produce outcomes that could shift the field or create meaningful new opportunities in rare cancer research.

8) Are preliminary data required?

Yes. The opportunity requires preliminary data paired with a disease-specific rationale. Applicants need to show evidence suggesting the approach is feasible and relevant to the rare cancer context.

9) What is a "disease-specific rationale" in this context?

A disease-specific rationale is a clear explanation of why the proposed work matters for the particular rare cancer type(s) or subtype(s) being studied, and why the approach is relevant and appropriate for that rare cancer context.

10) Do the preliminary data have to come from the exact rare cancer subtype being proposed?

No. The preliminary data do not have to be generated directly in the exact rare cancer subtype proposed. Data from related cancers, adjacent biological systems, model platforms, or other relevant contexts may be acceptable if the application persuasively explains why the findings translate and justify the proposed next steps for the rare cancer setting.

11) What should applicants do if their preliminary data come from a related cancer or model system?

They should make a persuasive case for translation: explain why those findings are relevant to the rare cancer type(s) or subtype(s), how they support feasibility, and why they justify advancing to the next developmental step in the rare cancer context.

12) What outcomes is the program trying to achieve?

The central goal is to generate high-impact findings and open new lines of investigation that could meaningfully advance rare cancer research and ultimately benefit patients, including potential advances in understanding, prevention, diagnosis, or treatment.

13) Who is eligible to apply?

Eligibility is listed as unrestricted, meaning the competition is broadly open rather than limited to a narrow applicant class (based on the information provided).

14) How many awards are expected to be made?

The anticipated number of awards is 15.

15) What is the application deadline?

The original closing date for applications is November 18, 2026.

16) When was this funding opportunity created?

The opportunity was created on June 17, 2026.

17) Is there a maximum award amount (award ceiling)?

An award ceiling is referenced, but it is not specified in the provided information. The maximum per-award funding amount would need to be confirmed in the full announcement materials.

18) What makes an application competitive based on the description provided?

Key expectations include: (1) a strong rare-cancer-focused justification, (2) supporting preliminary data (even if derived from related contexts) with a persuasive translation argument, and (3) a research plan positioned to produce outcomes that could shift the field or create meaningful new opportunities for rare cancer research and patient impact.

19) Is patient impact an explicit goal of the award?

Yes. The program emphasizes research that could meaningfully advance rare cancer knowledge and care and ultimately benefit patients.

20) What administrative entity runs this opportunity?

It is administered through the Defense Health Agency Contracting Activity (DHACA) under the Department of Defense Rare Cancers Research Program (RCRP).